Psoriatic Arthritis News

Editor’s note: This is a developing news story. Please check back soon for updates.

Sotyktu significantly outperformed placebo for the treatment of psoriatic arthritis in a phase 3 trial, meeting key endpoints at 16 weeks, according to late-breaking data presented at the American Academy of Dermatology annual meeting.

ORLANDO — Interleukin-23 inhibitors may be able to reduce the risk of developing psoriatic arthritis among patients with psoriasis, according to a speaker at the American Academy of Dermatology Annual Meeting.

It has been 5 years since the start of the COVID-19 pandemic, which forced many providers to embrace telehealth.

Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference product manufacturer, Janssen Pharmaceuticals, which set timelines for their market entries.

In honor of American Heart Month, Healio Dermatology interviewed experts and explored the connection between skin disease and heart health.

Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio Dermatology Chief Medical Editor, discusses hot topics in the field with leading experts.

Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio Dermatology Chief Medical Editor, discusses hot topics in the field with leading experts.

Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio Dermatology Chief Medical Editor, discusses hot topics in the field with leading experts.